Catamenial epilepsy: Hormonal aspects

Gynecological Endocrinology

Volumn 26, Issue 11, 2010, Pages 783-790

  Verrotti, Alberto ^a   Laus, Melissa ^a   Coppola, Giangennaro ^b   Parisi, Pasquale ^c   Mohn, Angelika ^a   Chiarelli, Francesco ^a  

^a UNIVERSITY OF CHIETI   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

allopregnenolone; androstenediol; Catamenial epilepsy; DHEAS; estrogens; progesterone; testosterone; THDOC

Indexed keywords

4 AMINOBUTYRIC ACID A RECEPTOR; ACETAZOLAMIDE; ANDROSTENEDIOL; CARBAMAZEPINE; CLOBAZAM; CLOMIFENE; CLONAZEPAM; ESTROGEN; ESTROGEN RECEPTOR; GANAXOLONE; LAMOTRIGINE; LEUPRORELIN; MEDROXYPROGESTERONE ACETATE; PHENYTOIN; PRASTERONE SULFATE; PROGESTERONE; TESTOSTERONE; TRIPTORELIN; VALPROIC ACID;

ANOVULATION; CATAMENIAL EPILEPSY; DEPRESSION; HORMONAL THERAPY; HORMONE SENSITIVITY; HUMAN; LUTEAL PHASE; MENSTRUAL CYCLE; MYOCLONUS SEIZURE; PATHOPHYSIOLOGY; PREVALENCE; PRIORITY JOURNAL; REVIEW; SEDATION; SIDE EFFECT;

ADOLESCENT; ADULT; ANTICONVULSANTS; EPILEPSY; ESTROGENS; FEMALE; HUMANS; MENSTRUAL CYCLE; NEUROTRANSMITTER AGENTS; PREVALENCE; PROGESTERONE; YOUNG ADULT;

EID: 77958021146     PISSN: 09513590     EISSN: 14730766     Source Type: Journal    
DOI: 10.3109/09513590.2010.490606     Document Type: Review

References (92)

1. Tempkin O. The falling sickness: a history of epilepsy from the Greeks to the beginnings of modern neurology. Baltimore: The Johns Hopkins Press; 1945.
2. Locock C. Discussion. Analysis of fifty-two cases of epilepsy observed by the author. Med Times Gaz 1857;14:524-526.
3. Gowers WR. Epilepsy and other chronic convulsive diseases. Their causes, symptoms, and treatment. London: J&A Churchill;1881.
4. Duncan S, Read CL, Brodie MJ. How common is catamenial epilepsy? Epilepsia 1993;34:827-831.
5. Herzog AG, Klein P, Ransil BJ. Three patterns of catamenial epilepsy. Epilepsia 1997;38:1082-1088.
6. Tuveri A, Paoletti AM, Orru M, Melis GB, Marotto MF, Zedda P, Marrosu F, Sogliano C, Marra C, Biggio G, et al. Reduced serum level of THDOC, an anticonvulsant steroid, in women with perimenstrual catamenial epilepsy. Epilepsia 2008;49:1221-1229.
7. Reddy DS. Perimenstrual catamenial epilepsy. Women's Health 2007;3:95-206.
8. Taubøll E, Lundervold A, Gjerstad L. Temporal distribution of seizures in epilepsy. Epilepsy Res 1991;8:153-165.
9. Herzog AG, Harden CL, Liporace J, Pennell P, Schomer DL, Sperling M, Fowler K, Nikolov B, Shuman S, Newman M. Frequency of catamenial seizure exacerbation in women with localization-related epilepsy. Ann Neurol 2004;56:431-434.
10. Bazan AC, Montenegro MA, Cendes F, Min LL, Guerreiro CA. Menstrual cycle worsening of epileptic seizures in women with symptomatic focal epilepsy. Arq Neuropsiquiatr 2005;63:751-756.
11. Marques-Assis L. Influence of menstruation on epilepsy. Arq Neuropsiquiatr 1981;39:390-395.
12. Morrell MJ. Epilepsy in women: the science of why it is special. Neurology 1999;53:S42-S48.
13. Foldvary-Schaefer N, Falcone T. Catamenial epilepsy: patho-physiology, diagnosis, and management. Neurology 2003;61:S2-S15.
14. Reddy DS, Rogawski MA. Neurosteroid replacement therapy for catamenial epilepsy. Neurotherapeutics 2009;6:392-401.
15. Pennell PB. Antiepileptic drugs during pregnancy: what is known and which AEDs seem to be safest? Epilepsia 2008;49:S43-S55.
16. Smith SS. Estrogen administration increases neuronal responses to excitatory amino acids as a long term effect. Brain Res 1989;503:354-357.
17. Wong M, Moss R. Long-term and short-term electrophysio-logical effects of estrogen on the synaptic properties of hippocampal CA1 neurons. J Neurosci 1992;12:3217-3225.
18. Kawakami M, Teresawa E, Ibuki T. Changes in multiple unit activity in the brain during the estrous cycle. Neuroendocrinol 1970;6:30-48.
19. Woolley CS, McEwen BS. Roles of estradiol and progesterone in regulation of hippocampal dendritic spine density during the estrous cycle in the rat. J Comp Neurol 1993;336:293-306.
20. Woolley CS, McEwen BS. Estradiol regulates hippocampal dendritic spine density via an N-methyl-D-aspartate receptor-dependent mechanism. J Neurosci 1994;14:7680-7687.
21. Pfaff DW, Keiner M. Estradiol-concentrating cells in the rat amygdala as part of a limbic-hypothalamic hormone-sensitive system. In: Eleftheriou B, editor. The neurobiology of the amygdala. New York: Plenum Publishing; 1973. pp 775-792.
22. Simerly RB, Chang C, Muramatsu M, Swanson LW. Distribution of androgen and estrogen receptor mRNA-containing cells in the rat brain: an in situ hybridization study. J Comp Neurol 1990;294:76-95.
23. McEwen BS. Nongenomic and genomic effects of steroids on neural activity. Trends Pharmacol Sci 1991;12:141-147.
24. Finn DA, Gee KW. The influence of estrus cycle phase on neurosteroid potency at the GABA-A receptor complex. J Pharmacol Exp Ther 1993;265:1374-1379.
25. Wallis CJ, Luttge WG. Influence of estrogen and progesterone on glutamic acid decarboxylase activity in discrete regions of rat brain. J Neurochem 1980;34:609-613.
26. Luine VN, Renner KJ, McEwen BS. Sex-dependent differences in estrogen regulation of choline acetyltransferase are altered by neonatal treatments. Endocrinology 1986;119:874-878.
27. Logothetis J, Harner R, Morrel F. The role of estrogens in catamenial exacerbation of epilepsy. Neurology 1959;9:352-360.
28. Backstrom T. Epileptic seizures in women related to plasma estrogen and progesterone during the menstrual cycle. Acta Neurol Scand 1976;54:321-347.
29. Jacono JJ, Robinson J. The effects of estrogen, progesterone, and ionized calcium on seizures during the menstrual cycle in epileptic women. Epilepsia 1987;28:571-577.
30. Lin TY, Greenblatt M, Soloman HC. A polygraphic study of one case of petit mal epilepsy: effects of medication and menstruation. Electroencephalogr Clin Neurophysiol 1952;4: 351-355.
31. El-Khayat HA, Soliman NA, Tomoum HY, Omran MA, El-Wakad AS, Shatla RH. Reproductive hormonal changes and catamenial pattern in adolescent females with epilepsy. Epilepsia 2008;49:1619-1626.
32. Paul SM, Purdy RH. Neuroactive steroids. FASEB J 1992;6: 2311-2322.
33. Majewska MD, Harrison NL, Schwartz RD, Barker JL, Paul SM. Steroid hormone metabolites are barbiturate-like modulators of the GABA receptor. Science 1986;232:1004-1007.
34. Gee KW, McCauley LD, Lan NC. A putative receptor for neurosteroids on the GABA receptor complex: the pharmacological properties and therapeutic potential of epalons. Crit Rev Neurobiol 1995;9:207-227.
35. Valera S, Ballivet M, Bertrand D. Progesterone modulates a neuronal nicotinic acetylcholine receptor. Proc Natl Acad Sci USA 1992;89:9949-9953.
36. Hsueh AJW, Peck EJ, Clark JH. Control of uterine estrogen receptor levels by progesterone. Endocrinology 1976;98:438-444.
37. Herzog AG, Friedman MN, Freund S, Pascual-Leone A. Transcranial magnetic stimulation evidence of a potential role for progesterone in the modulation of premenstrual cortico-cortical inhibition in a woman with catamenial seizure exacerbation. Epilepsy Behav 2001;2:367-369.
38. Bonuccelli U, Melis GB, Paoletti AM, Fioretti P, Murri L, Muratorio A. Unbalanced progesterone and estradiol secretion in catamenial epilepsy. Epilepsy Res 1989;3:100-106.
39. Corpechot C, Young J, Calvel M,Wehrey C, Veltz JN, Touyer G, Mouren M, Prasad VV, Banner C, Sjovall J. Neurosteroids: 3-hydroxy-5-pregnan-20-one and its precursors in the brain, plasma and steroidogenic glands of male and female rats. Endocrinology 1993;133:1003-1009.
40. Harrison NL, Majewska MD, Harrington JW, Barker JL. Structure-activity relationships for steroid interactions with the-aminobutyric acid receptor complex. J Pharmacol Exp Ther 1987;241:346-353.
41. Lambert JJ, Belelli D, Peden DR, Vardy AW, Peters JA. Neurosteroid modulation of GABA-A receptors. Prog Neu-robiol 2003;71:67-80.
42. Hosie AM, Wilkins ME, da Silva HM, Smart TG. Endogenous neurosteroids regulate GABA-A receptors through two discrete transmembrane sites. Nature 2006;444:486-489.
43. Rapkin AJ, Morgan M, Goldman L, Brann DW, Simone D, Mahesh VB. Progesterone metabolite allopregnanolone in women with premenstrual syndrome. Obstet Gynecol 1997;190:709-714.
44. Wang M, Seippel L, Purdy RH, Backstrom T. Relationship between symptom severity and steroid variation in women with premenstrual syndrome: study on serum pregnenolone, pregnenolone sulfate, 5-pregnane-3,20-dione and 3-hydroxy-5-pregnan-20-one. J. Clin Endocrinol Metab 1996;81:1076-1082.
45. Genazzani AR, Petraglia F, Bernardi F, Casarosa E, Salves-troni C, Tonetti A. Circulating levels of allopregnanolone in humans: gender, age and endocrine influences. J Clin Endocrinol Metab 1998;83:2099-2103.
46. Cooper EJ, Johnston GA, Edwards FA. Effects of a naturally occurring neurosteroid on GABA-A IPSCs during development in rat hippocampal or cerebellar slices. J Physiol 1999;521:437-449.
47. Belelli D, Casula A, Ling A, Lambert JJ. The influence of subunit composition on the interaction of neurosteroids with GABA-A receptors. Neuropharmacology 2002;43:651-661.
48. Bixo M, Andersson A, Winblad B, Purdy RH, Backstrom T. Progesterone, 5-pregnane-3,20-dione and 3-hydroxy-5-preg-nane-20-one in specific regions of the human female brain in different endocrine states. Brain Res 1997;764:173-178.
49. Stoffel-Wagner B. Neurosteroid biosynthesis in the human brain and its clinical implications. Ann NY Acad Sci 2003;1007:64-78.
50. Herzog AG, Frye CA. Seizure exacerbation associated with inhibition of progesterone metabolism. Ann Neurol 2003;53:390-391.
51. Joels M, Karst H, Krugers HJ, Lucassen PJ. Chronic stress: implications for neuronal morphology, function and neuro-genesis. Front Neuroendocrinol 2007;28:72-96.
52. Joels M. Steroid hormones and excitability in the mammalian brain. Front Neuroendocrinol 1997;18:2-48.
53. Reddy DS. Is there a physiological role for the neurosteroid THDOC in stress-sensitive conditions? Trends Pharmacol Sci 2003;24:103-106.
54. Reddy DS, Kulkarni SK. Proconvulsant effects of neuroster-oids pregnenolone sulfate and dehydroepiandrosterone sulfate in mice. Eur J Pharmacol 1998;345:55-59.
55. Kokate TG, Juhng KN, Kirkby RD, Llamas J, Yamaguchi S, Rogawski MA. Convulsant actions of the neurosteroid pregnenolone sulfate in mice. Brain Res 1999;831:119-124.
56. Williamson J, Mtchedlishvili Z, Kapur J. Characterization of the convulsant action of pregnenolone sulfate. Neuropharma-cology 2004;46:56-864.
57. Rush ME, Blake CA. Serum testosterone concentrations during the 4-day estrous cycle in normal and adrenalecto-mized rats. Proc Soc Exp Biol Med 1982;169:216-221.
58. Leranth C, Hajszan T, MacLusky NL. Androgens increase spine synapse density in the CA1 hippocampal subfield of ovariectomized female rats. J Neurosci 2004;24:495-499. (Pubitemid 38112381)
59. Doodipala SR. The role of neurosteroids in the pathophysiol-ogy and treatment of catamenial epilepsy. Epilepsy Research 2009;85:1-30.
60. Reddy DS. Testosterone modulation of seizure susceptibility is mediated by neurosteroids 3a-androstanediol and 17b-estradiol. Neuroscience 2004;129:195-207.
61. Reddy DS. Anticonvulsant activity of the testosteronederived neurosteroid 3-androstanediol. NeuroReport 2004;15:515-518.
62. Kaminski RM, Livingood MR, Rogawski MA. Allopregnano-lone analogs that positively modulate GABA receptors protect against partial seizures induced by 6-Hz electrical stimulation in mice. Epilepsia 2004;45:864-867.
63. Kaminski RM, Marini H, Kim WJ, Rogawski MA. Antic-onvulsant activity of androsterone and etiocholanolone. Epilepsia 2005;46:819-827.
64. Rogawski MA, Loscher W. The neurobiology of antiepileptic drugs. Nat Rev Neurosci 2004;5:553-564.
65. Isojarvi JI, Tauboll E, Herzog AG. Effect of antiepileptic drugs on reproductive endocrine function in individuals with epilepsy. CNS Drug 2005;19:207-223. (Pubitemid 40460661)
66. Murialdo G, Galimberti CA, Gianelli MV. Effects of valproate, phenobarbital, and carbamazepine on sex steroid setup in women with epilepsy. Clin Neuropharmacol 1998;21:52-58.
67. Morrell MJ, Guidice L, Flynn KL. Predictors of ovulatory failure in women with epilepsy. Ann Neurol 2002;52:704-711.
68. Herzog AG, Friedman MN. Menstrual cycle interval and ovulation in women with localization-related epilepsy. Neurology 2002;57:2133-2135.
69. Bauer J, Burr W, Elger CE. Seizure occurrence during ovulatory and anovulatory cycles in patients with temporal lobe epilepsy: a prospective study. Eur J Neurol 1998;5:83-88.
70. Mattson RH, Kamer JM, Cramer JA, Caldwell BV. Seizure frequency and the menstrual cycle: a clinical study. Epilepsia 1981;22:242.
71. Zimmerman AW, Holder DT, Reiter EO, Dekaban AS. Medroxyprogesterone acetate in the treatment of seizures associated with menstruation. J Pediatr 1973;83:959-963.
72. Mattson RH, Cramer JA, Caldwell BV, Siconolfi BC. Treatment of seizures with medroxyprogesterone acetate: preliminary report. Neurology 1984;34:1255-1258.
73. Foldvary-Schiaefer N, Harden C, Herzog A, Falcone T. Hormones and seizures. Cleve Clin J Med 2004;71:S11-S18.
74. Herzog AG. Intermittent progesterone therapy of partial complex seizures in women with menstrual disorders. Neurology 1986;36:1607-1610.
75. Herzog AG. Progesterone therapy in women with complex partial and secondary generalized seizures. Neurology 1995;45:1600-1662.
76. Herzog AG. Progesterone therapy in women with epilepsy: a 3-year follow-up. Neurology 1999;52:1917-1918.
77. Herzog AG. Clomiphene therapy in epileptic women with menstrual disorders. Neurology 1988;38:432-434.
78. Bauer J, Wildt L, Flugel D, Stefan H. The effect of a synthetic GnRH analogue on catamenial epilepsy: a study in ten patients. J Neurol 1992;239:284-286.
79. Haider Y, Barnett DB. Catamenial epilepsy and goserelin. Lancet 1991;338:1530.
80. Reid B, Gangar KF. Catamenial epilepsy and goserelin. Lancet 1992;339:253-1253.
81. Livingston S. Comprehensive management of epilepsy in infancy, childhood and adolescence. Springfield, IL: Charles C Thomas; 1972.
82. Ross IP. Acetazolamide therapy in epilepsy. Lancet 1958;2:1308-1309.
83. Ansell B, Clarke E. Epilepsy and menstruation. The role of water retention. Lancet 1956;2:1232-1235.
84. Lombroso CT, Forxythe I. A long-term follow-up of acetazolamide (Diamox) in the treatment of epilepsy. Epilep-sia 1960;1:493-500.
85. Millichap JG, Woodbury DM, Goodman BS. Mechanism of the anticonvulsant action of acetazolmide, a carbonic anhydrase inhibitor. J Pharmacol Exp Ther 1995;115:251-258.
86. Reddy DS, Rogawski MA. Chronic treatment with the neuroactive steroid ganaxolone in the rat induces antic-onvulsant tolerance to diazepam but not to itself. J Pharmacol Exp Ther 2000;295:1241-1248.
87. Ramaratham S. Successful treatment of a patient with refractory catamenial epilepsy with lamotrigine. SYCP Epilepsy 2003;10:18-20.
88. Rogawski MA, Reddy DS. Neurosteroids: endogenous modulators of seizure susceptibility. In: Rho JM, Sankar R, Cavazos JE, editors. Epilepsy: scientific foundations of clinical practice. New York: Marcel Dekker; 2004. pp 319-355.
89. Reddy DS, Rogawski MA. Enhanced anticonvulsant activity of neuroactive steroids in a rat model of catamenial epilepsy. Epilepsia 2001;42:303-310.
90. Reddy DS, Rogawski MA. Neurosteroid replacement therapy for catamenial epilepsy. Neurotherapeutics 2009;6:392-401.
91. Phillipps GH. Structure-activity relationships in steroidal anaesthetics. J Steroid Biochem 1975;6:607-613.
92. Reddy DS, Woodward R. Ganaxolone: a prospective overview. Drugs future 2004;29:227-242.